Tumor promotion by Mdm2 splice variants unable to bind p53

Jordan S. Fridman, Eva Hernando, Michael T. Hemann, Elisa De Stanchina, Carlos Cordon-Cardo, Scott W. Lowe

Research output: Contribution to journalArticlepeer-review

75 Scopus citations

Abstract

The Mdm2 oncoprotein physically associates with p53 and antagonizes its tumor suppressor functions. Previous studies indicate that some tumors express alternatively or aberrantly spliced Mdm2 variants that are unable to bind p53, but whether these actively contribute to carcinogenesis or are a byproduct of cancer progression has been unclear. In this study, we examined the ability of full-length Mdm2 and several tumor-derived splice variants to modulate tumor development in Eμ-myc transgenic mice. We report that several tumor-derived Mdm2 splice variants promote tumorigenesis in a manner that is comparable with full-length Mdm2. Our results imply that the current paradigm for understanding Mdm2 action during oncogenesis is incomplete, and its splice variants contribute to human cancer.

Original languageEnglish
Pages (from-to)5703-5706
Number of pages4
JournalCancer Research
Volume63
Issue number18
StatePublished - 15 Sep 2003
Externally publishedYes

Fingerprint

Dive into the research topics of 'Tumor promotion by Mdm2 splice variants unable to bind p53'. Together they form a unique fingerprint.

Cite this